Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.
CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.
1277 Results
Background Reducing the number of active compounds for lifelong HIV treatment is of interest, especially to reduce potential long-term side effects. The Rumba study is the first randomized clinical trial evaluating the impact on the viral reservoir, inflammation and metabolic parameters of switch from a 2nd generation integrase inhibitor (INSTI)-based triple ART regimen towards DTG/3TC vs.…
Background Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single-tablet regimen (STR) with no recommendations from the manufacturer regarding crushing or dissolving tablets for adult use. However, oral ingestion may be impractical for hospitalized individuals requiring enteral feeding. Despite some healthcare institutions administering B/F/TAF in crushed or dissolved form in such cases, there is limited clinical evidence regarding the efficacy…
Background For some individuals with HIV-1 infection who have failed multiple antiretroviral regimens and have limited treatment options, there is an urgent need for new antiretroviral drugs with novel mechanisms of action. Albuvirtide (ABT) is an HIV-1 fusion inhibitor and 3BNC117 is an HIV-specific, broadly neutralizing monoclonal antibody. We aimed to assess the efficacy and safety…
Background The A5324 trial investigated intensification with dolutegravir (DTG) +/- maraviroc (MVC) on neuropsychological performance (NP) in persons with HIV (PWH) and neurocognitive impairment (NCI) on suppressive ART. Intensification with these drug classes does not reduce the reservoir size or residual viremia, but changes in other virological parameters have been observed. For example, intensification with integrase…
Background Antiretroviral (ARV) guidelines (WHO, DHHS, IAS-USA, EACS, BHIVA) suggest HIV viral load (VL) monitoring every 3 to 6 months. No trial has evaluated intervals >6 months. There are few recommendations regarding the interval between patient assessments. During the COVID lockdown, clinical assessment and VL monitoring were less frequent in the Chelsea-Westminster (C-W) HIV cohort…
Background For people with HIV (PWH) on antiretroviral therapy (ART), transitioning to bimonthly long-acting (LA) injectable cabotegravir (CAB) plus rilpivirine (RPV) can be done either directly (non-OLI) or after an optional one-month oral lead-in (OLI). Recent data suggest lower CAB trough concentrations (Ctrough) with non-OLI initiation. This study aimed to assess pharmacokinetics (PK) and virological…
Background Since the beginning of HIV treatment, changes in the use of antiretroviral (ARV) drugs have often led to changes in HIV resistance mutation patterns. The integrase inhibitor (INI) class has benefited from many developments: first raltegravir (RAL) and elvitegravir (EVG), followed by dolutegravir (DTG), cabotegravir (CAB) and bictegravir (BIC). The aim of this study…
Background ARTISTRY-1 is a Phase 2/3 study evaluating the safety and efficacy of the complete regimen of the capsid inhibitor lenacapavir (LEN) given with the integrase strand-transfer inhibitor (INSTI) bictegravir (BIC) compared to remaining on a complex multi-tablet regimen. Virologically suppressed participants with no known INSTI resistance mutations were enrolled in the Phase 2 portion. At…
Background Transmitted or acquired antiretroviral (ARV) drug resistance limits treatment options for people living with HIV-1 and may reduce the effectiveness of preexposure prophylaxis (PrEP). Novel treatment options with enhanced effectiveness and more convenient formulations have become available from 2016 to 2021. This study assessed the prevalence of plasma RNA and proviral DNA ARV drug…
Background African countries have shifted to dolutegravir (DTG)-based first-line HIV treatment. However, population-based studies of resistance trends through DTG roll-out in sub-Saharan Africa are extremely limited. Methods We analyzed data from the Rakai Community Cohort Study, an open population-based cohort, during five survey rounds between 2012 and 2022. Consenting people aged 15-49 years were interviewed…